{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062041","form_type":"8-K","ticker":"ORGO","cik":"0001661181","company_name":"Organogenesis Holdings Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.978358+00:00","generated_at":"2026-06-08T06:54:30.981012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Organogenesis Q3 revenue down 7% to $108.5M; net income rises to $3.2M; guides FY rev down 1-4%","bullets":["Net revenue $108.5M, down $8.3M YoY; Advanced Wound Care fell 7% to $101.4M; Surgical & Sports Med fell 2% to $7.2M.","Net income $3.2M ($0.02/sh) vs $0.2M ($0.00/sh) in Q3 2022; adjusted net income $5.3M vs $5.1M.","Adjusted EBITDA $16.0M, up 38% from $11.6M; operating income $8.1M vs $1.8M.","FY2023 guidance: net revenue $433-446M (down 1-4% YoY); net income $4-9M; adjusted net income $11-17M.","Revenue impacted by LCD withdrawal issues; profitability improved despite headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062041","json":"https://secwatch.observer/filing/0000950170-23-062041.json","markdown":"https://secwatch.observer/filing/0000950170-23-062041.md","text":"https://secwatch.observer/filing/0000950170-23-062041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023062041/0000950170-23-062041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023062041/orgo-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:54:30.981012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b6846a09867ccd96625c05927f9543890fea334","claim":"Organogenesis Holdings Inc. reported the third quarter ended September 30, 2023 results: revenue $108.5 million, net income $3.2 million, EPS $0.02 per share. Guidance reaffirmed.","evidence_excerpt":"Net revenue of $108.5 million for the third quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661181/000095017023062041/0000950170-23-062041-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$108.5 million"},{"label":"Net income","value":"$3.2 million"},{"label":"EPS","value":"$0.02 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}